Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and Israel.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.068|
|52 Week High||AU$0.061|
|52 Week Low||AU$0.21|
|1 Month Change||-6.85%|
|3 Month Change||4.61%|
|1 Year Change||-67.62%|
|3 Year Change||-24.44%|
|5 Year Change||36.00%|
|Change since IPO||-94.15%|
Recent News & Updates
Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|RSH||AU Medical Equipment||AU Market|
Return vs Industry: RSH underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.
Return vs Market: RSH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: RSH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: RSH's weekly volatility (11%) has been stable over the past year.
About the Company
Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and Israel. The company develops, produces, and sells mobile health applications. Its products include Wheezo, an asthma management tool to help user understand their asthma by providing information, such as triggers, symptoms, medication usage, and other events.
Respiri Fundamentals Summary
|RSH fundamental statistics|
Is RSH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RSH income statement (TTM)|
|Cost of Revenue||AU$1.26m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.015|
|Net Profit Margin||-796.56%|
How did RSH perform over the long term?See historical performance and comparison
Is Respiri undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RSH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RSH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RSH is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.
PE vs Market: RSH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RSH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RSH is overvalued based on its PB Ratio (6.5x) compared to the AU Medical Equipment industry average (5x).
How is Respiri forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Respiri performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RSH is currently unprofitable.
Growing Profit Margin: RSH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RSH is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.
Accelerating Growth: Unable to compare RSH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RSH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).
Return on Equity
High ROE: RSH has a negative Return on Equity (-145.84%), as it is currently unprofitable.
How is Respiri's financial position?
Financial Position Analysis
Short Term Liabilities: RSH's short term assets (A$8.9M) exceed its short term liabilities (A$1.5M).
Long Term Liabilities: RSH's short term assets (A$8.9M) exceed its long term liabilities (A$70.7K).
Debt to Equity History and Analysis
Debt Level: RSH's debt to equity ratio (0%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RSH's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RSH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RSH has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 13% each year.
What is Respiri current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RSH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RSH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RSH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...
CEO Compensation Analysis
Compensation vs Market: Marjan's total compensation ($USD1.16M) is above average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Marjan's compensation has been consistent with company performance over the past year.
Experienced Management: RSH's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: RSH's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.
Respiri Limited's employee growth, exchange listings and data sources
- Name: Respiri Limited
- Ticker: RSH
- Exchange: ASX
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$49.153m
- Shares outstanding: 722.84m
- Website: https://respiri.co
- Respiri Limited
- 432 St Kilda Road
- Suite 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:27|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.